COCP Stock Forecast: Cocrystal Pharma, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Cocrystal Pharma, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Cocrystal Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (24): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
COCP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on COCP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 18 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 June 2025 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $6.00 |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | $10 → $7.00 |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Dec 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Oct 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 May 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Jan 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Nov 2020 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $4.50 |
| 8 July 2020 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 June 2020 | Noble Capital Markets | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for COCP.
This page is one stock. Monday covers all of them.
COCP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
COCP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Cocrystal Pharma, Inc. returned +1.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
COCP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 41.7×
- Price / book
- 6.8×
- EV / EBITDA
- —
Cheaper than 5% of US stocks
Cheaper than 12% of US stocks
- Revenue growth (YoY)
- −53.3%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 5% of US stocks
- Return on equity
- −219.1%
- Return on assets
- −83.6%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cocrystal Pharma, Inc. has a market value of $18.7M and an enterprise value of $15.1M.
Revenue in the twelve months to 30 June 2026: $330K.
Net income over the same four quarters: −$9.9M, a −3011.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$8.0M.
Cocrystal Pharma, Inc. employs 10 people — $33K of revenue per employee.
Data provided by Twelve Data
COCP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at COCP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Cocrystal Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about COCP
What is the COCP stock price forecast for 2026-2027?
The median 12-month analyst price target for Cocrystal Pharma, Inc. is $8, with estimates ranging from $6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is COCP stock a buy right now?
Of the 2 analysts covering Cocrystal Pharma, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cocrystal Pharma, Inc. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank COCP?
As at 21 Nov 2026, Cocrystal Pharma, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
Will COCP stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $8, and Ticker Nerd's factor model ranks Cocrystal Pharma, Inc. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the COCP stock forecast for 2030?
No analyst covering Cocrystal Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COCP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $10 over the next 12 months.
How has COCP stock performed over the past year?
Cocrystal Pharma, Inc. returned +1.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cocrystal Pharma, Inc. do?
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases. The company’s current programs target the replication mechanisms of norovirus, influenza, coronaviruses, and hepatitis C, with an emphasis on oral direct-acting candidates designed for treatment and prevention settings.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious viral diseases. The company’s current programs target the replication mechanisms of norovirus, influenza, coronaviruses, and hepatitis C, with an emphasis on oral direct-acting candidates designed for treatment and prevention settings. Its pipeline includes drug development efforts that span discovery, preclinical work, and clinical-stage studies, supported by structure-based technologies aimed at identifying differentiated antiviral compounds. Cocrystal Pharma also engages in research partnerships and funding activities that help advance its antiviral portfolio and related scientific programs. Headquartered in Bothell, Washington, Cocrystal Pharma plays a specialized role in the biotechnology market by addressing unmet needs in infectious disease therapeutics through targeted antiviral innovation.
CEO Dr. Sam Lee Ph.D. · 10 employees · United States · https://www.cocrystalpharma.com